Table 2.
Baseline distributions of patients treated in their better-seeing eye (BSE) or worse-seeing eye (WSE) and utility values by BSE/WSE
| BCVA health state (letters) | Patients at model entry (%) | Patients whose treated eye was their BSE (%) | Utility when treated eye was the BSE | Utility when treated eye was the WSE |
|---|---|---|---|---|
| 86–100 | 0 | 50a | 0.850 | 0.850 |
| 76–85 | 4 | 50 | 0.758 | 0.836 |
| 66–75 | 20 | 22 | 0.685 | 0.821 |
| 56–65 | 33 | 22 | 0.611 | 0.807 |
| 46–55 | 20 | 21 | 0.537 | 0.793 |
| 36–45 | 13 | 15 | 0.464 | 0.779 |
| 26–35 | 9 | 10 | 0.390 | 0.764 |
| ≤25 | 1 | 0a | 0.353 | 0.750 |
| Death | 0 | – | 0.000 | 0.000 |
Utilities for the BSE were from a published study; WSE utilities were assumed to be proportional to those for the BSE [33]
BCVA best-corrected visual acuity, RADIANCE Ranibizumab and vPDT Evaluation in Myopic Choroidal Neovascularization
aAssumption, no patients were in these groups at baseline in the RADIANCE study